Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 7, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 650,000 ordinary shares of 25 pence each.
- Purchase Price: 1,518.43 pence per share.
- Treasury Shares Held: 124,108,000 shares following the transaction.
- Shares in Issue: 5,824,610,876 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 25, 2005. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (124,108,000) against subsequent filings.
- Confirm the total number of shares in issue (5,824,610,876) excluding Treasury shares.
- Review the Annual General Meeting minutes from May 25, 2005, to confirm the scope of the share repurchase authority.
- Check for any subsequent Form 6-K filings regarding further share buybacks or cancellations.